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Abstract
Purpose of Review Pre-eclampsia remains a leading world-
wide cause of maternal death and of perinatal morbidity.
There remains no definitive treatment except delivery of the
fetus.
Recent Findings Recent insights into the cardiovascular chang-
es that are evident prior to, during, and persist after pre-
eclampsia have improved understanding of the underlying path-
ophysiology—disruption of normal endothelial function and de-
creased nitric oxide bioavailability. S-nitrosoglutathione
(GSNO) is an endogenous S-nitrosothiol that acts as a NO pool
and, by replenishing or preventing the breakdown of GSNO,
endothelial dysfunction can be ameliorated. GSNO reductase
inhibitors are a novel class of drug that can increase NO
bioavailability.
Summary GSNO reductase inhibitors have demonstrated im-
provement of endothelial dysfunction in animal models, and
in vivo human studies have shown them to be well tolerated.
GSNOR inhibitors offer a potentially promising option for the
management of pre-eclampsia.
Keywords Pre-eclampsia . S-nitrosoglutathione . GSNO .
GSNO reductase inhibitors
Introduction
Pre-eclampsia is a multisystem disorder, which manifests clini-
cally as hypertension and proteinuria after 20 weeks of pregnan-
cy. Pre-eclampsia occurring at or close to term is usually treat-
able by delivery with minimal risk to mother or baby. However,
in approximately 1% of pregnancies the condition is early onset,
and this usually coincides with worse severity, particularly be-
fore 32 weeks gestation. In this situation, expeditious conserva-
tive management focusing on control of hypertension and sei-
zure prevention to gain fetal maturity is key. Although antihy-
pertensive medication is used, there is no current treatment that
targets the underlying pathophysiology [1, 2].
The underlying pathological processes of pre-eclampsia are
hypothesized to occur in two stages [3]. Abnormal placenta-
tion is suggested to be the initiating event resulting in reduced
placental perfusion, in turn, leading to increased oxidative
stress, which, in combination with a maternal predisposition,
results in endothelial dysfunction. This manifest by changes in
a number of signaling pathways and homeostatic mecha-
nisms, but impaired nitric oxide (NO) bioavailability [4] is
thought to play a major role in the maternal manifestations
of pre-eclampsia such as hypertension and likewise platelet
activation, proteinuria, and oedema. More recently, abnormal
pre-pregnancy blood pressure has been shown to relate to risk
of pre-eclampsia [5], and abnormal arterial function in the first
trimester is associated with higher likelihood of PE [6]. So the
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prevailing wisdom relating to the placenta’s central role in pre-
eclampsia is likely to be an over simplification.
Relationship of Pre-eclampsia and Endothelial
Dysfunction
Pre-eclampsia causes disruption of normal endothelial barrier,
structure, and function, resulting in a state of endothelial dys-
function which is characterized by decreased NO bioavailabil-
ity. Arterial and cardiac function are abnormal before and
during the disease’s clinical manifestation [7, 8••, 9].
Consequently, there is an increase in vascular tone [10, 11],
hypertension [12, 13], increased permeability of the vascula-
ture and resultant proteinuria, and oedema [14, 15]. There is
also a shift towards a proinflammatory and prothrombotic
state [4, 16], particularly as a result of platelet activation [17].
Women who have had pre-eclampsia are at a higher long-
term risk of adverse cardiovascular outcomes including
stroke, myocardial dysfunction, and death due to a vascular
event [18–21]. Indeed, the major risk factors for pre-eclampsia
are those classically associated with endothelial dysfunction
and long-term cardiovascular morbidity including systolic hy-
pertension, obesity, diabetes mellitus, and hypercholesterolae-
mia [22–25]. It is now suggested that there is pre-existing pre-
pregnancy endothelial dysfunction in women who go on to
develop pre-eclampsia. Studies starting prior to pregnancy and
following women throughout pregnancy have allowed an in-
sight into haemodynamic changes in normal pregnancy [26,
27]; abnormal cardiovascular adaptation in early pregnancy
may be associated with birth weight [28]. The degree to which
these risk factors affect endothelial function pre-pregnancy
and the degree to which they are exacerbated by pregnancy
and pre-eclampsia are currently under investigation.
Asymmetric dimethylarginine (ADMA) is an endogenous
eNOS inhibitor. Levels of ADMA are higher in women at
high risk of pre-eclampsia as determined by abnormal uterine
artery Doppler waveform [7]. And, in those women who go
on to develop pre-eclampsia, there is an inverse correlation of
ADMA with FMD, suggesting that increased ADMA may
reduce NO bioavailability and thus contribute to the develop-
ment of pre-eclampsia. FMD is reduced in the early second
trimester in women who go on to develop both pre-term and
term pre-eclampsia when compared to those who do not be-
come hypertensive or develop gestational hypertension [29].
Decreased bioavailability of NO provides a potential ther-
apeutic target for novel drug therapy of pre-eclampsia. NO
donors, used in a research context, reduce blood pressure
(BP), and platelet activation in pre-eclampsia whilst having
no detrimental effect on placental perfusion [1, 30].
Prophylaxis with glyceryl trinitrate (GTN) in high-risk wom-
en reduces overall adverse outcome related to ‘placental syn-
dromes’ though not the incidence of pre-eclampsia itself [2,
31]. However, the utility of most NO donors including GTN is
limited by hypotension, side effects, and tachyphylaxis.
The primary source of NO is endothelial nitric oxide syn-
thase (eNOS). NO is extremely short-lived and, in order to
have more than a transient effect following synthesis, it must
be stored in a stable, bioavailable form. The primary receptor
of NO is soluble guanylate cyclase (sGC), with subsequent
activation of this enzyme and the production of cyclic GMP.
cGMP acts as a secondary messenger and is involved in the
regulation of multiple intracellular pathways, notably smooth
muscle relaxation and platelet inhibition. S-nitrosothiols are a
class compounds that have an NO group attached to the thiol
(RSH) moiety by a single chemical bond. S-nitrosothiols re-
lease the NO moiety by mechanisms including exposure to
light, heat, and transition metals, in addition to enzymatic
bioactivation. As such, these compounds, particularly GSNO
act as a stable intracellular bioavailable NO pool [32]. The
precise pathways for cellular nitrosothiol formation and deg-
radation remain unclear, although the following schematic
(Fig. 1), adapted from Smith et al. [33•], outlines potential
mechanisms. Another potentially valuable property of
GSNO is that glutathione acts as a free-radical ‘sink’.
Increased levels of GSNOmay facilitate NO-mediated pro-
cesses, whereas increased activity GSNOR (the regulatory
enzyme in GSNO catabolism) may impair these processes
through reduction of NO bioavailability. It has been proposed
that, due to the fact that GSNOR interferes with processes
relevant to cardiovascular health, inhibition of GSNOR may
be beneficial [32]. The potential sites of therapeutic interven-
tion in the NO pathway are outlined in Fig. 2.
GSNO in Pre-eclampsia
GSNO was first used over 20 years ago in relation to the
treatment of pre-eclampsia in a woman with severe HELLP
(haemolysis, elevated liver enzymes and low platelets) syn-
drome (thought to be an extreme variant of pre-eclampsia)
which was refractory to conventional management.
Improvements in blood pressure and platelet count were noted
almost immediately following commencement of GSNO in-
fusion [35]. Further investigation of the use of GSNO in se-
vere pre-eclampsia showed improvements in blood pressure,
uterine artery pulsatility index (which is classically abnormal-
ly high in pre-eclampsia), and a reduction in platelet activation
[30]. It is also notable that other studies investigating the re-
plenishment of NO, using GTN patches, suggest that im-
proved outcomes and prolongation of pregnancy may be
achievable [31, 36, 37].
We have previously performed an in vivo study of GSNO
infusion in pre-eclampsia in six women with early-onset pre-
eclampsia [38]. GSNO resulted in a reduction in augmentation
index, an indirect measure of NO-sensitive small vessel tone,
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from baseline (P < 0.001) with significant changes occurring
at infusion rates of 30 and 100μg/min GSNO (mean reduction
in AIx-75: −6 and −13% respectively, P < 0.05). Reductions
in both diastolic (P = 0.017) and systolic central BPs
(P = 0.008) were also seen. The reduction in central BP was
significant at 100 μg/min GSNO (P < 0.05). Similarly MAP
dose dependently reduced with increasing GSNO infusion
rate (P = 0.004). Peripheral systolic BP was unchanged, but
peripheral diastolic BP fell (P = 0.012). No significant chang-
es were found in central or peripheral pulse pressures, and
maternal heart rate remained constant.
Platelet surface P-selectin expression, a marker of platelet
activation, was lower following GSNO infusion (P = 0.03).
GSNO infusion in pre-eclampsia may also reduce proteinuria.
Fig. 2 Simplified schematic of
NO/S-nitrosothiol pathways and
potential therapeutic targets.
Reproduced from Johal et al. [34]
Fig. 1 Potential transnitrosation
signaling pathways. NOS nitric




CBR1 carbonyl reductase, Trx
thioreduxin, TrxR thioreduxin
reductase. Adapted from Smith
et al. [33•]. Reproduced with
permission
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The urine protein:creatinine ratios were lower in relation to
their starting levels at the conclusion of the GSNO infusion.
The fetal heart rate did not change during GSNO infusion,
and there were no significant cardiotocograph changes. There
were no changes in maternal uterine, fetal umbilical, middle
cerebral, or ductus venosus Doppler PI at any dose of GSNO.
Whilst the primary purpose of the study was to test the
hypothesis that replacement of NO with different doses of
GSNO in early-onset pre-eclampsia would restore arterial
function, neonatal, andmaternal safety outcomeswere collect-
ed. The perinatal outcomes were not different from fetuses of
similar weight and gestation that were not exposed to GSNO.
There were no maternal adverse outcomes, although three
women reported headache, which resolved with paracetamol
administration.
Further preliminary investigation on the quantification of
GSNO in women with severe pre-eclampsia, has suggested
that GSNO is found in lower circulating quantities than in
women without pre-eclampsia (personal unpublished data).
Although S-nitrosoglutathione has potential as a thera-
peutic option for pre-eclampsia, there are significant diffi-
culties in its administration. GSNO degrades rapidly when
exposed to light and heat so it requires long-term storage in
a freezer. After reconstitution, GSNO requires immediate
intravenous infusion and needs to be protected from light
and kept cool. These factors limit its utility as a treatment
option, particularly in the developing world, where the bur-
den of disease and where the availability of reliable refrig-
eration are often limited.
GSNO Reductase Inhibitors Identification
and In Vivo Studies
Following the increased awareness of GSNO as a major play-
er in NO metabolism and as a repository for NO, which oth-
erwise has a short biological half-life, the role of GSNO re-
ductase was further investigated. Various studies found that
there was deregulation of GSNOR leading to lower SNO con-
centrations and adverse effects on the respiratory, cardiovas-
cular, and gastrointestinal systems. Conversely, mice with a
genetic deletion of GSNOR are protected from asthma-like
airway hyperresponsivity by the increased SNO concentra-
tions acting as an endogenous bronchodilator. This, in turn,
led to a targeted high throughput screening of commercially
available compounds by N30 Pharmaceuticals (now Nivalis
Therapeutics) (Boulder, CO, USA) to identify compounds that
demonstrated potential as GSNOR inhibitors [39•]. Following
identification and synthesis selected, compounds were further
tested for cytotoxicity. Minimal toxicity was observed towards
epithelial lung cells, and a majority of those studied also dem-
onstrated minimal cytochrome P450 inhibition. Similarl no
evidence of mutagenicity was found in a bacterial mutagen
screen, and in vivo toxicology studies in mice demonstrated
that the substances were well tolerated although at the highest
doses alterations to liver function tests were found on
prolonged exposure [40••].
Intravenous administration of a novel GSNOR inhibitor
(N6022), daily for over 7 days showed that it was well toler-
ated and there were few side-effects. Those that were demon-
strated, e.g., cough, nasal congestion, and headache were well
tolerated and were not dose-limiting. A further phase 1 study
of administration of an orally administered GSNOR inhibitor
(N91115) found that it was well tolerated in healthy subjects at
up to 2.5 times to expected therapeutic exposure, for over
14 days. Pharmacokinetics studied support; a twice-daily dos-
ing regime [41]. This dosing regime, particularly in oral form,
would have considerable advantages over GSNO administra-
tion, as discussed above.
A phase 2 trial of the GSNOR inhibitor, N91115 (now
named cavosonstat) has been performed in 138 adults with a
homozygous F508del-CFTR mutation at doses of 200 and
400 mg bd compared to placebo. All participants were also
receiving standard treatment with Orkambi (Vertex
Pharmaceuticals, Boston, MA, USA), a combination of
lumacaftor and ivacaftor. This trial has very recently reported
and found no difference in the primary outcome, change in
FEV1, across the groups (http://ir.nivalis.com/press-releases/
detail/56). The future of GSNO reductase inhibitors in the
treatment of CF is uncertain.
Effect of GSNOR Inhibitors on Endothelial Function
Flow-mediated dilatation in pre-eclampsia has been shown to
be consistently lower in pre-eclampsia compared to normo-
tensive pregnancies [42–47], compatible with poorer endothe-
lial function. In pre-eclamptic pregnancies complicated by
IUGR, FMD is further reduced [44, 48]. FMD is a non-
invasive marker of endothelial function and, as such, NO bio-
availability. In pre-eclampsia, it has been suggested that alter-
ations in FMD may be, in part, due to alterations in the down-
stream effect of cGMP rather than due to the availability of
NO, per se [49].
The novel GSNO reductase inhibitor N6338, was tested in
a hypertensive rat model (Dahl-S rats fed a high salt (4%NaCl)
diet) and compared to a normotensive group. GSNO reductase
activity was tested in both the heart and aortic tissue and was
significantly reduced by the addition of N6338. Further
in vitro studies showed that the addition of L-NMMA, an
eNOS inhibitor, attenuated the effect of GSNO reductase in-
hibition in pre-constricted (using phenylephrine) aortic rings.
This demonstrated the dependence of N6338 effects on the
classic cGMP/NO model of smooth muscle relaxation.
Flow-mediated dilatation was then tested 24 h after adminis-
tration of N6338. This showed that the GSNOR inhibitor
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prevented an l-NMMA reduction in FMD. In the hypertensive
rats, inhibition of GSNO reductase caused a fall in vascular
resistance, a reduction in blood pressure and restored FMD to
a level similar to normotensive rats [32]. Importantly, this
study demonstrated reversal of hypertension-induced renal
changes of hypertension: this would be a valuable therapeutic
benefit in pre-eclampsia and accords with our finding of a
reduction in proteinuria with GSNO infusion [38].
Conclusion
Pre-eclampsia remains a significant cause of maternal and
neonatal mortality and morbidity worldwide. Although of sei-
zure prevention with MgSO4 and awareness of the need to
detect and treat hypertension has made some headway into
improving outcomes, there remains no treatment modality that
targets the endothelial dysfunction that underlies that patho-
logical process that manifests as pre-eclampsia.
The only drug currently under investigation that targets the
NO pathway is sildenafil. To date the results of studies of
sildenafil in pre-eclampsia have not demonstrated a benefit.
Our group has demonstrated that intravenous infusion of
GSNO has cardiovascular, platelet, and, possibly, renal effects
on women with severe early pre-eclampsia that could be ben-
eficial and could warrant further investigation. There are con-
siderable difficulties in the preparation, administration, and
refrigeration storage of GSNO.
The recent discovery and development of GSNO reductase
inhibitors albeit in other therapeutic areas provides a promising
option. Several of these which have passed cytotoxic and muta-
gen assessment and have proven themselves to be well tolerated
in phase 1 studies. They lend themselves to use in the second
and third trimesters of pregnancy. Animal studies showing im-
provement in endothelial function and hypertension with GSNO
reductase inhibitors are consistent with our observations of the
effect of GSNO in human. The particular advantage of GSNOR
inhibitors is the ability to administer orally.
The inertia engendered because of concerns over drug de-
velopment in pregnancy has in the longer term led to a thera-
peutic wilderness in which conditions potentially amenable to
treatment are overlooked [2]. At least on a mechanistic level,
GSNOR inhibitors offer a potentially promising option for the
management of pre-eclampsia.
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